March 29, 2024
PassPort Technologies, Inc.

PassPort Technologies, Inc. Announces Positive Interim Phase I Results ofZolmitriptan Transdermal Microporation System for the Treatment of Acute Migraine

PassPort Technologies, Inc. (PPTI), based in San Diego, a clinical-stage drug and medical device
development company, today announced positive interim results from the Phase 1 (Part A) clinical
trial of Zolmitriptan PassPort® utilizing its proprietary transdermal microporation system for thetreatment of acute migraine. Zolmitriptan is an FDA-approved prescription medication used fortreating migraine symptoms.
Zolmitriptan PassPort®, a needle-free combination
system consisting of a microporation device andzolmitriptan patch, was applied on the individual’s
upper arm to deliver zolmitriptan into the systemic
circulation via micropores painlessly created in the

Zolmitriptan PassPort®
demonstrated
tolerability and rapid
delivery of zolmitriptan.

skin.
The open-label, randomized, crossover study consisting of 32 healthy volunteers tested thetolerability and pharmacokinetics of Zolmitriptan PassPort® with 3 different doses (0.75 mg, 1.5mg, and 3.0 mg) compared to oral administration of 2.5 mg zolmitriptan.
Zolmitriptan PassPort® was well-tolerated with no serious adverse events. Zolmitriptan wasdetected in the plasma only 2 minutes after Zolmitriptan PassPort® administration, much fasterthan 15 minutes seen for oral administration. The relative bioavailability of Zolmitriptan PassPort®
was approximately 160 to 200% compared to oral zolmitriptan.
"We are pleased with the tolerability and pharmacokinetics of Zolmitriptan PassPort® in Phase
1 Part A study. Our Zolmitriptan PassPort® is expected to demonstrate significant advantages offaster onset of action and higher pain relief for migraine patients with severe nausea and patients
who are non-responsive to oral triptans. It will provide a Best-in-Class product option." said
President and CEO Tomoyuki Fujisawa.
Part B study, currently underway, will evaluate the transdermal administration of a single dose atalternative sites, the subject's abdomen and upper thigh. The final results will be available to thepublic in Q3 2024.
PPTI holds exclusive global rights to develop and commercialize the Zolmitriptan PassPort® butintends to out-license for further clinical development and commercialization.

About PassPort Technologies, Inc.
As a cutting-edge biotechnology entity, PPTI is committed to the swift development and patientdelivery of innovative pharmaceuticals through the PassPort® system. The company aims toconstantly develop technologies that serve the pharmaceutical industry and broader life sciences
sectors. PPTI’s mission is to advance global health outcomes. Further details can be found athttps://passport-tech.com.
About PassPort® Technology
The PassPort® System integrates patented painless skin microporation and dry patch
formulation technologies to regulate drug delivery through the micropores created in the skin. This
innovative system enables transdermal delivery of not only small molecules but also peptides,proteins, and RNAs for therapeutics and infection vaccines.
Forward-Looking Statement
Except for historical information, all the statements, expectations, and assumptions containedin this Press Release are forward-looking statements. Actual results may differ materially fromthose explicit or implicit in the forward-looking statements. Important factors that could cause actual
results to differ materially include: the early phase of the clinical trial; risks associated with the drug
development process; competition; reliance on key personnel; and other risks described in other
PassPort Technologies, Inc. press releases and presentations.
■For inquiries regarding this matter, please contact:
PassPort Technologies, Inc.
Hirotoshi Adachi, Ph.D.
Chief Operating Officer
5580 Morehouse Drive, Suite 120, San Diego, CA 92121, USA
TEL: +1-858-888-4188
E-mail: info@passport-tech.com
URL: https://passport-tech.com/